Patents Assigned to Universite de Strasbourg
-
Publication number: 20240075699Abstract: A process for manufacturing by moulding an optical component includes at least the following steps: a step of providing at least one mould, during which a glass profile is provided, said glass profile including a doping according to a predetermined geometry and having a refractive index profile depending on said doping and including at least an end including at least a structuring obtained by chemically etching of said doping, said structuring forming said at least one mould, and a moulding step, during which at least a moulding material suitable for forming at least an optical component is provided and arranged in said mould in order to shape said optical component.Type: ApplicationFiled: January 25, 2022Publication date: March 7, 2024Applicants: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DES SCIENCES APPLIQUEES, UNIVERSITE FERHAT ABBAS SETIF 1Inventors: Sylvain LECLER, Nacer Eddine DEMAGH, Assia GUESSOUM, Djamila BOUAZIZ, Zaid BOUHAFS
-
Patent number: 11879038Abstract: The present invention relates to a polymer foam, said polymer foam comprising pores forming an open-cell polymer foam, said polymer foam comprising a supramolecular gel inside pores, and said polymer foam comprising at least one enzyme. The present invention relates to a supramolecular gel; its preparation and its applications, notably in chemical synthesis and kinetic resolution, in particular of organic compounds. The present invention also relates to flow chemistry.Type: GrantFiled: September 9, 2020Date of Patent: January 23, 2024Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Loïc Jierry, Christophe Serra, Pierre Schaaf, Jennifer Rodon Fores, Fouzia Boulmedais
-
Patent number: 11838530Abstract: A method for concealing data in an image or a video stream inside a compression chain, being implemented by a computer and including a structuring and processing phase, during which at least one image is structured into blocks including coefficients, a phase of converting and quantifying blocks so as to generate converted and quantified coefficients, with entropic coding intended to code the converted and quantified coefficients. The method includes a step of concealing data, during which bits of the data are concealed by modifying converted and quantified coefficients located in a high frequency zone of at least some of the blocks that relate to the luminance component of the video stream and that are intra-coded. This modification is performed after the quantification but before the entropic coding.Type: GrantFiled: February 20, 2020Date of Patent: December 5, 2023Assignees: UNIVERSITE DE LORRAINE, UNIVERSITE DE STRASBOURGInventors: Jean-Marie Moureaux, Amine Chaabouni, Yann Gaudeau
-
Patent number: 11826403Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.Type: GrantFiled: October 20, 2020Date of Patent: November 28, 2023Assignees: UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, VAXINE PTY LTDInventors: Vincent Marion, Nikolai Petrovsky
-
Patent number: 11827747Abstract: The present invention concerns a polymer comprising repetitive units having the following formula (I) wherein R1 is H or Me; L is a linker; R2 is the side chain of an ?-amino acid being other than arginine; m is 0 or an integer comprised from 1 to 10; n is an integer comprised from 1 to 10; and X— is a counterion.Type: GrantFiled: May 6, 2020Date of Patent: November 28, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE STRASBOURGInventors: Fouzia Boulmedais, Delphine Chan-Seng, Nicolas Zydziak, Philippe Lavalle
-
Patent number: 11823799Abstract: The present invention provides a powerful tool to identify personalized therapeutic strategies. In particular, the invention provides methods for determining therapeutically targetable dominant signaling pathways in a cancer sample from a subject affected with a solid cancer, determining a treatment protocol for the subject, selecting a subject for a therapy, determining whether the subject is susceptible to benefit from a therapy, predicting clinical outcome of the subject, treating the subject and/or predicting the sensitivity of a solid cancer to a therapy.Type: GrantFiled: November 21, 2016Date of Patent: November 21, 2023Assignees: UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Dominique Bagnard, Aurore Fernandez, Laurent Jacob, Justine Fritz
-
H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer
Publication number: 20230349922Abstract: The present invention provides Histamine Receptor 2 antagonists and pharmaceutical compositions thereof for use in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers. The present invention also relates to methods for identifying candidate compounds that are useful in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers.Type: ApplicationFiled: August 11, 2021Publication date: November 2, 2023Applicants: Université de Strasbourg, Institut National de la Santé et de la Recherche MédicaleInventors: Thomas Baumert, Emilie Crouchet -
Patent number: 11773163Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.Type: GrantFiled: November 21, 2017Date of Patent: October 3, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE STRASBOURG, ETABLISSEMENT FRANçAIS DU SANG (EFS)Inventors: Pierre Mangin, Christian Gachet
-
Publication number: 20230256138Abstract: The present invention relates to a biomaterial comprising: —a membrane wound patch (a), made of a nanofibrous polymeric scaffold, —a hydrogel (b) including autologous or allogenic bone marrow-derived mesenchymal stem cells, and —a bone wound patch (c) being a nanofibrous scaffold made of polymers, wherein said scaffold has a surface coated with an interrupted coating made of multilayered droplets, said multilayered droplets being droplets composed of at least one layer pair consisting of a layer of polyanions and a layer of polycations, and wherein the bone wound patch (c) further comprises a bone growth factor; wherein the hydrogel (b) is included between the membrane wound patch (a) and the bone wound patch (c).Type: ApplicationFiled: May 14, 2020Publication date: August 17, 2023Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE STRASBOURGInventor: Nadia BENKIRANE-JESSEL
-
Patent number: 11718703Abstract: A rigid foam or composition allowing a rigid foam to be obtained made from polyurethane and/or polyisocyanurate. The rigid foam or composition includes polyols selected from polyester polyols and polyether polyols; the polyols include: 5 to 50% of a polyester polyol A by weight relative to the total weight of the polyols; and a polyol B selected from polyester polyols B and polyether polyols B. The polyester polyol A is of general formula Rx-Ry-Z-Ry?-Rx? in which Z is a C3 to C8 alcohol sugar chosen from glycerol, sorbitol, erythritol, xylitol, araditol, ribitol, dulcitol, mannitol and volemitol. Ry and Ry? are diesters of formula —OOC—Cn-COO— in which n is between 2 and 34, and Rx and Rx? are identical or different C2 to C12 monoalcohols.Type: GrantFiled: January 22, 2019Date of Patent: August 8, 2023Assignees: TEREOS STARCH & SWEETENERS BELGIUM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SOPREMA, UNIVERSITE DE STRASBOURGInventors: Pierre Etienne Bindschendler, Alexandru Sarbu, Rémi Perrin, Pierre Furtwengler, Luc Avérous, Andréas Redl
-
Publication number: 20230240788Abstract: A device for processing a video stream related to a specific operative procedure. The device includes: a video stream reception interface, a processor, and a memory storing instructions, such that when the instructions are executed by the processor, they configure the device for: receiving, via the video stream reception interface, the video stream having a sequence of images including an image to be processed which represents at least a portion of an anatomical element, the image to be processed being formed by processing elements; determining, by a processing function, whether or not a criterion is satisfied in the image to be processed; determining a state of progress associated with the image to be processed based on whether or not the criterion is satisfied, the state of progress being representative of a state of progress of an operative step of the specific operative procedure.Type: ApplicationFiled: June 11, 2021Publication date: August 3, 2023Applicants: FONDATION DE COOPERATION SCIENTIFIQUE, Université de Strasbourg, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, UNIVERSITÀ CATTOLICA DEL SACRO CUORE, INSTITUT DE RECHERCHE CONTRE LES CANCERS DE L'APPAREIL DIGESTIFInventors: Nicolas PADOY, Pietro MASCAGNI, Bernard DALLEMAGNE
-
Patent number: 11666599Abstract: The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).Type: GrantFiled: November 28, 2017Date of Patent: June 6, 2023Assignees: INSERM, INTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INRA, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, CNRS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURGInventors: Sébastien Roux, Thierry Plouvier, Julie Le Merrer, Jérôme Becker
-
Patent number: 11666628Abstract: The present disclosure relates to a BIN1 protein or a BIN1 nucleic acid sequence producing or encoding the same, for a use in the treatment of X-linked centronuclear myopathy. The present invention provides compositions and methods for treatment of X-linked centronuclear myopathy. The present invention relates to a method of delivering the BIN1 polypeptide to subjects with X-linked centronuclear myopathy.Type: GrantFiled: November 12, 2018Date of Patent: June 6, 2023Assignees: UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jocelyn Laporte, Valentina Lionello, Belinda Cowling
-
Patent number: 11666657Abstract: This invention pertains to protein-drug conjugates that may be used in the treatment of cancers and to pharmaceutical compositions containing the same. The protein-drug conjugate has the following formula (I), wherein: L is a cysteine-containing protein residue linked through one or more of the cysteine groups of the protein, R1 is selected from the group consisting of arylene, arylene-heteroarylene, heteroarylene-arylene and heteroarylene, n is an integer from 0 to 5, p and q are independently 0 or 1, R2, R3 and Z are spacers, u is 0 or 1 and T is a cleavable unit sensitive to hydrolases, k is 1 or 2 and D is a cytotoxic drug residue selected from dolastatin residues, which may be identical to or different from each other when k is 2, m is the mean payload-to-protein ratio (PPR) of the conjugate, which ranges from 0.1 to 16.Type: GrantFiled: May 15, 2018Date of Patent: June 6, 2023Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Alain Wagner, Sergii Kolodych, Oleksandr Koniev
-
Patent number: 11602578Abstract: The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.Type: GrantFiled: November 2, 2018Date of Patent: March 14, 2023Assignees: Université de Strasbourg, Institut National De La Sante Et De La Recherche Medicale (INSERM), Protip MedicalInventors: Philippe Lavalle, Pierre Schaaf, Nihal Engin Vrana, Angela Mutschler, Cynthia Calligaro, Lorène Tallet
-
Patent number: 11597936Abstract: The present invention relates to a nucleic acid coding for a human DGKk protein lacking a functional Proline Rich Region and/or a functional EPAPE repeated Region, and to its use in the treatment of fragile X syndrome in a patient in need thereof.Type: GrantFiled: September 26, 2017Date of Patent: March 7, 2023Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Hervé Moine, Ricardos Tabet
-
Patent number: 11549886Abstract: Dye-loaded fluorescent polymeric nanoparticles working as light-harvesting nano-antenna, which efficiently transfer the excitation energy to acceptor dyes and, therefore, amplifies emission of the latter are provided.Type: GrantFiled: June 21, 2018Date of Patent: January 10, 2023Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Andrey Klymchenko, Kateryna Trofymchuk, Andreas Reisch, Bohdan Andreiuk
-
Publication number: 20230003727Abstract: Zwitterionic luminescent polymeric nanoparticles, which include at least one luminescent dye and at least one random copolymer, and the method of preparing the zwitterionic luminescent polymeric nanoparticles. Also, the use of these zwitterionic luminescent polymeric nanoparticles in the medical field and in the biological research field for in vitro or in vivo detection or tracking of a target biological molecule.Type: ApplicationFiled: December 2, 2020Publication date: January 5, 2023Applicants: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Andrii KLYMCHENKO, Andreas REISCH, Anne RUNSER, Denis DUJARDIN
-
Publication number: 20220411493Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: ApplicationFiled: April 29, 2022Publication date: December 29, 2022Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas BAUMERT, Rajeevkumar Tawar
-
Patent number: 11530241Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.Type: GrantFiled: December 14, 2018Date of Patent: December 20, 2022Assignees: UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventor: Vincent Marion